For ALL, a total of seven studies with 120 patients who received CD22/CD19 CAR‐T cells were included in the meta‐analysis, in which 119 patients were eligible for the response evaluation, and 120 cases were used to assess the safety of dual‐targeting CAR‐T cells. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.